Last updated: 2026-09-16 12:18:20. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Soligenix, Inc. (SNGX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $0.36, with a market capitalisation of $7.85M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.28 to $2.86. This page covers its latest market performance, valuation, price trends and company information.
$7.85M | |
$0.36 | |
$1,217.98 | |
$0.28 | |
$0.36 | |
7.99K | |
354.20K | |
-- | |
$2.86 | |
$0.28 | |
-- | |
-- |
Soligenix, Inc. (SNGX) is trading at $0.36 in pre-market trading as of 2026-09-16 12:11:00, down 0.03% ($0.00) from the previous close of $0.36
Pre-market trading shows how investors are pricing SNGX before the regular session opens. The current pre-market price is near the previous close, indicating cautious early trading sentiment.
Over the past seven days, Soligenix, Inc. (SNGX) moved from $0.38 to $0.36, representing a decline of 5.26% ($0.02).
The stock traded between $0.36 and $0.39 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 143.16 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 3.1%
SNGX is currently trading at $0.36, placing it 3.1% of the way from its 52-week low of $0.28 to its 52-week high of $2.86. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely: The Public Health Solutions business segment includes development programs for RiVax, a ricin toxin vaccine candidate, GX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease and various vaccine programs, including a program targeting filoviruses and CiVax; and The Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte, utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL).
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 14 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Soligenix, Inc. (SNGX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.